Evidence map›Paper›PMID 24532228›Full record

ArticleMolecular biotechnology2014

High-yield expression in Escherichia coli, purification and application of budding yeast K2 killer protein.

Monika Podoliankaitė, Juliana Lukša, Gintautas Vyšniauskis, Jolanta Sereikaitė, Vytautas Melvydas, Saulius Serva, Elena Servienė

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biotechnology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Viruses · 2018
    Article
  2. Bioprotective Role of Yeasts.Microorganisms · 2015
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Monika PodoliankaitėLaboratory of Genetics, Institute of Botany, Nature Research Centre, Akademijos Str. 2, 08412, Vilnius, Lithuania.
Juliana Lukša
Gintautas Vyšniauskis
Jolanta Sereikaitė
Vytautas Melvydas
Saulius Serva
Elena Servienė
Nature Research Centre · LTVilnius Gediminas Technical University · LT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Saccharomyces cerevisiae K2 toxin is a highly active extracellular protein, important as a biocontrol agent for biotechnological applications in the wine industry. This protein is produced at negligible levels in yeast, making difficult to isolate it in amounts sufficient for investigation and generation of analysis tools. In this work, we demonstrate the use of a bacterial system for expression of the recombinant K2 protein, suitable for generation of antibodies specific for toxin of the yeast origin. Synthesis of the full-length S. cerevisiae K2 preprotoxin in Escherichia coli was found to be toxic to the host cell, resulting in diminished growth. Such effect was abolished by the introduction of the C-terminal truncation into K2 protein, directing it into non-toxic inclusion body fraction. The obtained protein is of limited solubility thus, facilitating the purification by simple and efficient chromatography-free procedure. The protein aggregates were successfully refolded into a soluble form yielding sufficient amounts of a tag-less truncated K2 protein suitable for polyclonal antibody production. Antibodies were raised in rabbit and found to be specific for detection of both antigen and native S. cerevisiae K2 toxin.

Indexed as

Amino Acid SequenceAnimalsAntibodiesCloning, MolecularEscherichia coliGene Expression Regulation, FungalKiller Factors, YeastRabbitsSaccharomyces cerevisiaeAntibodiesK2 killer toxinKiller Factors, Yeast

Identifiers

PMID24532228
OpenAlexW1986678390

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.